Antimicrobial Resistance (AMR) is one of the biggest medical concerns of modern times. In China, the incidence of AMR infections has increased steeply in the last ten years.

In the post-COVID world, this public health crisis is yet again beginning to take over the spotlight. The Center for Disease Control and Prevention (CDC) reports that the COVID-19 pandemic pushed back years of progress made combating AMR.

The threat of AMR infections is much worse—with hospital-acquired resistant infections and deaths increasing at least 15% during the first year of the pandemic.

This webinar explores why this is the right time to look beyond efforts to just curb drug-resistant infections and urgently address improving access to novel anti-infectives and issues surrounding their costs and surveillance. Central to this is the vital role of partnerships between biopharmaceutical companies who play different roles across an integrated global value chain, coming together in their combined expertise on AMR to provide innovative therapies to people impacted by acute and life-threatening illnesses.

For the first time, Melinta Therapeutics, Menarini Asia-Pacific and SciClone Pharmaceuticals will share the stage and shine a light on their collective vision to empower healthcare professionals with better drugs to ensure healthier lives for their patients. The Chief Executive Officers of these companies will discuss how their shared vision for this common cause has brought them together to license new therapies in China, facilitating greater access to anti-infective medicines to address the rising threat of AMR in China.

In this webinar, you will learn about:

• The burden and the dangers of AMR as a public health crisis
• Historical challenges of developing drugs to combat AMR and the importance of partnerships in addressing these challenges
• Barriers to access that are impacting patient outcomes
• How responsible and forward-looking drug licensing partnerships can increase and expand access to patients and address unmet needs for patients in Asia
• The future of AMR treatment and drug development in China